Business
First expansion cohort for MATINS trial part 2
First expansion cohort for MATINS trial part 2.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 8193V Faron Pharmaceuticals Oy 11 April 2019 \n\nFaron Pharmaceuticals Oy\n(\"Faron\" or the \"Company\")\n \nColorectal cancer selected as a first expansion cohort for MATINS trial part 2\n \nSelection based on observed activation of patient's immune system and shrinkage of colorectal cancer metastasis in the lung\n \nTURKU - FINLAND, 11 April 2018 - Faron Pharmaceuticals Oy (AIM: FARN), the clinical stage biopharmaceutical company, today announces that the cohort expansion part of its phase I/II MATINS clinical trial investigating the safety and efficacy of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy, will begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing has been determined. \n \nClevegen is a novel anti-Clever-1 antibody, which causes changes in the immune environment of solid tumours by switching Clever-1 positive immune suppressive myeloid cells to immune active macrophages. This immune switch results in increased number of active tumour-killing CD8+ cells leading to robust anti-tumour activity in pre-clinical models (Viitala et al. (2019) Clinical Cancer Research, on-line DOI:10.1158/1078-0432.CCR-18-3016), and also reviewed by Mantovani and Bonecchi (2019) (Clinical Cancer Research, on-line DOI:10.1158/1078-0432.CCR-19-0483).\n \nThe decision to target colorectal cancer during the cohort expansion stage of the MATINS Phase I/II study (part 2) follows previously reported early data from the ongoing dose escalation and safety stage of MATINS which has now recruited four subjects with no safety concerns at 0.3 and 1.0 mg/kg dosing and has moved to 3 mg/kg dosing level. All dosed patients have, thus far, shown a switch in their immune profile towards more immune activation, observed as an increase in CD8+ cells, an increased CD8/CD4 ratio, decreased regulatory T-cells (T-regs) and a high appearance of mobile NK cells in the blood. \n \nAs previously reported, Faron has also received a tumour imaging report of a patient with colorectal cancer, which indicates significant shrinkage of lung metastasis (classified as a partial response according to the RECIST classification). Positively, the patient has also shown a decrease in the tumour load marker CEA (carcinoembryonic antigen), which has normalized a...